Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 4Prostatic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Multiple Myeloma 1Lung Neoplasms 1Ewing's Sarcoma Family of Tumors 1Colorectal Neoplasms 1Carcinoma, Adenosquamous 1Carcinoma 1Breast Diseases 1Advanced Non-Hematologic Malignancies 1Advanced Cancer 1

Interventions

exemestane 4entinostat 4Fulvestrant 4ribociclib 3palbociclib 3abemaciclib 3Anastrozole 3Trastuzumab 2Letrozole 2Gonadotropin-Releasing Hormone 2AZD9833 2tucatinib 1trastuzumab deruxtecan 1taxane 1pertuzumab 1pembrolizumab 1ipatasertib 1figitumumab 1elacestrant 1dactolisib 1atezolizumab 1Watchful Waiting 1Trabectedin 1Tamoxifen 1STX-478 1RAD1901 1Paclitaxel 1Metformin 1Lapatinib 1Imlunestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Diseases × figitumumab × Clear all
NCT00678626 2015-05-04

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Pfizer

Phase 2 Withdrawn
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡